Skip to main content

Table 4 Cox proportional hazards regression of all patients for intracranial progression

From: Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

Variables

Hazard ratio (95% CI)

p value

Age > 65

1.12 (0.771 to 1.615)

0.561

Sex (male)

0.93 (0.617 to 1.395)

0.718

Smoking

1.06 (0.594 to 1.900)

0.838

EGFR mutation

 L858R only

Reference

 

 Del 19 only

0.94 (0.643 to 1.363)

0.729

 Uncommon mutation

2.26 (0.802 to 6.341)

0.123

 Complex mutations

2.95 (1.050 to 8.264)

0.040

Initial brain metastases number ≥ 3

1.16 (0.800 to 1.685)

0.432

RT to brain before 1st PD

0.80 (0.535 to 1.191)

0.270

Brain tumor excision

0.91 (0.608 to 1.362)

0.209

TKI

 Gefitinib

Reference

 

 Erlotinib

0.85 (0.568 to 1.283)

0.447

 Afatinib

1.00 (0.602 to 1.662)

1.000